Deshawn 'DJ' Chow describes his experiences with sickle cell disease, stating, "A year ago, he found out about a new treatment called Casgevy that could end his years-long battle with pain." This reflects the urgency he felt as he awaited the transformative potential of this gene editing therapy.
The rollout of Casgevy has been slow due to complex manufacturing and insurance issues. Experts note, "The slow rollout underscores the complicated nature of commercializing cutting-edge medical treatments and getting them to patients." This highlights both the promise and challenges of innovative therapies.
Collection
[
|
...
]